Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Elicio Therapeutics, Inc. - Common Stock (NQ:ELTX)

4.140 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,755
Open 4.140
Bid (Size) 3.860 (200)
Ask (Size) 3.980 (300)
Prev. Close 4.140
Today's Range 4.140 - 4.140
52wk Range 2.660 - 16.00
Shares Outstanding 29,798,399
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These stocks have an unusual volume in today's session ↗
Via Chartmill
Which stocks have an unusual volume on Thursday? ↗
Via Chartmill

Performance

YTD
-48.6%
-48.6%
1 Month
-58.7%
-58.7%
3 Month
-62.1%
-62.1%
6 Month
-48.8%
-48.8%
1 Year
-48.4%
-48.4%

More News

Read More
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
Which stocks are moving after the closing bell on Wednesday? ↗
Via Chartmill
Top movers in Wednesday's session ↗
Via Chartmill
Elicio Therapeutics (NASDAQ:ELTX) Q1 2026 Results Show Extended Cash Runway Ahead of Key Phase 2 Data Readout ↗
Via Chartmill
News headline image
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
From Elicio Therapeutics Inc.
Via GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Monday's session: top gainers and losers ↗
Via Chartmill
Gapping stocks in Monday's session ↗
Via Chartmill
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics to Present at the Bank of America Healthcare Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Elicio Therapeutics, Inc. - Common Stock publicly traded?
Yes, Elicio Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Elicio Therapeutics, Inc. - Common Stock trade on?
Elicio Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Elicio Therapeutics, Inc. - Common Stock?
The ticker symbol for Elicio Therapeutics, Inc. - Common Stock is ELTX on the Nasdaq Stock Market
What is the current price of Elicio Therapeutics, Inc. - Common Stock?
The current price of Elicio Therapeutics, Inc. - Common Stock is 4.140
When was Elicio Therapeutics, Inc. - Common Stock last traded?
The last trade of Elicio Therapeutics, Inc. - Common Stock was at 06/22/26 04:00 PM ET
What is the market capitalization of Elicio Therapeutics, Inc. - Common Stock?
The market capitalization of Elicio Therapeutics, Inc. - Common Stock is 123.37M
How many shares of Elicio Therapeutics, Inc. - Common Stock are outstanding?
Elicio Therapeutics, Inc. - Common Stock has 123M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.